Accrelist Ltd (QZG) Fair Value & Analysis
Healthcare · SG · Market cap 20.9M SGD
Fair value as of: Jul 4, 2026
From 8 valuation models · updated today
Share price +16.1% over the past month.
Price vs Fair Value (12 months)
12‑month range 0.0310 SGD – 0.0660 SGD · fair‑value band 0.0293 SGD – 0.0358 SGD · the 0.0650 SGD price screens above the 0.0358 SGD fair value. As of Jul 4, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Accrelist Ltd (QZG) currently trades at 0.0650 SGD, while our model-based Fair Value estimate is 0.0358 SGD — implying the stock looks roughly 45.0% overvalued today. We read business quality at 66/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, Accrelist Ltd generated revenue of 15.6M SGD at a net margin of -1.7%. Revenue grew 27.8% year over year. It earns a return on equity of -10.4%. Net debt stands at 3.6M SGD. Fundamentals as of Jul 4, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 4, 2026. TTM = trailing twelve months.
About the company
Accrelist Ltd., an investment holding company, engages in the medical aesthetics business in Singapore, Malaysia, and Indonesia. It operates through three segments: Mechanical Business Unit (MBU), Aesthetic Medical Services (AMS), and Others segment. The MBU segment offers mould design and fabrication services for consumer electronics, household appliances, automotive, and computer peripherals, as well as precision plastic injection moulding services for customers' finished products. Its AMS segment offers aesthetic services and solutions, including cosmetic dermatology and skin laser services. The company is also involved in the operation of aesthetic medical clinics; retail sale of pharmaceutical and medical goods; and development and distribution of original design manufacturer (ODM) clinical skincare products and other non-ODM products. The company was formerly known as WE Holdings Ltd. and changed its name to Accrelist Ltd. in November 2016. Accrelist Ltd. was founded in 1986 …
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Accrelist Ltd reported revenue of 15.6M SGD in FY2026 versus 241M SGD in FY2022, a compound −49.5%/yr. Reported net income was −264K SGD in FY2026.
Is QZG fairly valued? → Check now
Similar stocks
6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 4, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc H1CA34 | R$96.00 | R$25.67 | -73% |
| Fresenius SE FSNUY | $11.27 | $8.25 | -27% |
| Q0F Q0F | 2.76 SGD | 1.28 SGD | -54% |
| 5225 5225 | 8.70 MYR | 2.61 MYR | -70% |
| IHHHF IHHHF | $1.71 | $1.26 | -26% |
| Rede D'Or São Luiz S.A RDOR3 | R$33.83 | R$46.94 | +39% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Accrelist Ltd (QZG) undervalued?
What is the fair value of QZG?
What is the quality score of QZG?
What is the revenue of Accrelist Ltd (QZG)?
What is the net profit margin of QZG?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.